查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1700176

2032 年急性缺血性腦中風診斷和治療市場預測：按藥物類型、診斷方法、療法、最終用戶和地區進行的全球分析

Acute Ischemic Stroke Diagnosis and Treatment Market Forecasts to 2032 - Global Analysis By Drug Type, Diagnosis Method, Treatment, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球急性缺血性腦中風(AIS) 診斷和治療市場預計在 2025 年達到 64 億美元，到 2032 年將達到 111 億美元，預測期內的複合年成長率為 8.1%。

急性急性缺血性腦中風（AIS）是由動脈阻塞引起的嚴重腦血管事件，導致腦血流減少和潛在的神經元損傷。基於人工智慧的中風診斷和新型血栓移除設備等新興趨勢正在塑造市場動態，並推動神經血管領域的製藥和醫療設備公司之間的競爭。

根據國際糖尿病聯盟的最新資料，2021年全球約有5.37億20至79歲人群患有糖尿病，預計到2030年這一數字將增至6.43億，到2045年將增至7.83億。

中風發生率增加

全球範圍內急性缺血性腦中風（AIS）盛行率的上升是市場發展的關鍵促進因素。人口老化和心血管疾病負擔加重導致中風發生率上升。此外，久坐不動的生活方式、不良飲食和吸煙等生活方式因素進一步加劇了中風的風險。政府和醫療保健組織也在加強宣傳宣傳活動，以促進早期發現和早期療育。中風患者的急劇增加正在推動AIS診斷和治療市場的成長。

治療選擇有限

AIS 市場的主要限制因素之一是有效治療的治療窗口有限。中風治療的時間敏感度限制了某些治療方法（如溶栓和血栓切除術）的應用。診斷延遲或患者到醫療機構就診延遲往往會導致錯過最佳治療機會。這些挑戰凸顯了改善醫療基礎設施和加快診斷通訊協定的必要性。治療時間有限是市場擴張的重大障礙。

人工智慧與遠端醫療的融合

人工智慧（AI）與遠端醫療的融合為AIS市場創造了巨大的機會。人工智慧診斷工具可以提高中風檢測的準確性和速度，從而實現及時干預。遠端醫療促進了遠距會診，使專家能夠在服務不足的地區做出即時治療決策。此外，人工智慧預測分析可以幫助識別高風險個體並採取預防措施。預計對數位健康解決方案的投資增加將推動該領域的創新和成長。

治療相關併發症的風險

可能出現的治療相關併發症對 AIS 市場構成威脅。血栓溶解療法和機械血栓切除術等治療方法具有出血、感染和血管損傷等風險。此外，先進治療方法的高成本及其相關風險可能會限制其在資源受限的環境中的應用。確保患者安全同時保持治療效果仍是一項重大挑戰。透過改進通訊協定和更安全的治療方案解決這些問題對於市場成長至關重要。

COVID-19的影響：

COVID-19 疫情對 AIS 診斷和治療市場產生了各種影響。一方面，疫情期間對醫療基礎設施的關注和快速診斷的需求加速了先進技術的採用。然而，這次疫情凸顯了遠端醫療和遠端監控的重要性，預計它們將在疫情後的中風管理中發揮更大的作用。

抗血小板藥物市場預計將在預測期內佔據最大佔有率

抗血小板藥物因其在預防血栓形成方面的有效性，預計將在預測期內佔據最大的市場佔有率。這些藥物對於治療急性缺血性腦中風至關重要，並可降低復發風險。抗血小板藥物因其在預防中風方面的有效性而被廣泛應用於臨床實踐中。藥物配方和給藥方法的進步提高了患者的依從性和治療效果。此外，中風發病率的上升、對預防醫學的日益重視以及持續的研究和開發預計將導致更有效的抗血小板療法的推出，並加強其在市場上的地位。

預計成像技術領域在預測期內將實現最高的複合年成長率。

由於電腦斷層掃描和 MRI 等影像技術的進步提高了診斷的準確性和速度，預計影像技術領域將在預測期內見證最高成長率。對早期和準確的中風檢測的需求推動了對先進診斷成像解決方案的需求不斷成長。預計醫療保健基礎設施投資的增加（尤其是在發展中地區）將推動影像技術的採用。此外，診斷成像模式的持續進步將提高其能力，從而帶來更好的患者治療效果，而醫療保健提供者和技術公司之間的合作可能會加速尖端成像解決方案的採用。

佔比最大的地區：

預計北美地區將在預測期內佔據最大的市場佔有率。人們對中風症狀和及時干預的重要性的認知不斷提高，推動了對先進診斷和治療解決方案的需求。主要市場參與者的存在和對研發的持續投資進一步加強了該地區的市場地位。政府旨在改善中風治療的措施促進了這一成長。此外，高血壓和糖尿病等生活型態相關風險因素的盛行率上升也有望推動市場發展。

複合年成長率最高的地區：

在預測期內，由於醫療保健基礎設施的快速發展和醫療保健支出的增加，預計亞太地區將呈現最高的複合年成長率。中國、印度和日本等國家處於領先地位，大力投資醫療技術和基礎設施。人們對中風的認知不斷提高以及早期診斷和治療的重要性正在推動市場需求。政府的優惠政策和改善醫療保健的努力也促進了這一成長。中風盛行率的上升以及高血壓和糖尿病等相關風險因素預計將進一步推動市場擴張。

提供免費客製化：

訂閱此報告的客戶將獲得以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球急性缺血性腦中風診斷和治療市場（按藥物類型）

  • 纖溶藥物
  • 抗血小板藥物
  • 抗凝血劑
  • 神經保護劑
  • 其他藥物類型

6. 全球急性缺血性腦中風診斷與治療市場（依診斷方法）

  • 影像技術
    • 電腦斷層掃描 (CT)
    • 磁振造影（MRI）
    • CT血管造影術
    • 磁振血管造影術
  • 血液檢查
  • 心電圖
  • 其他診斷方法

7. 全球急性缺血性腦中風診斷與治療市場（依療法）

  • 藥物治療
  • 外科手術和介入治療
  • 其他治療

8. 全球急性缺血性腦中風診斷和治療市場（按最終用戶）

  • 門診手術中心
  • 診斷中心
  • 醫院
  • 研究機構
  • 其他最終用戶

9. 全球急性缺血性腦中風診斷與治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Abbott Laboratories
  • BIOTRONIK SE & Co KG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE Healthcare Technologies Inc.
  • Genentech, Inc. by Roche Group
  • Hitachi, Ltd.
  • Integral Diagnostics（IDX）Group
  • Koninklijke Philips NV
  • Mediso Kft.
  • Medtronic PLC
  • Memorial Health
Product Code: SMRC29079

According to Stratistics MRC, the Global Acute Ischemic Stroke Diagnosis and Treatment Market is accounted for $6.4 billion in 2025 and is expected to reach $11.1 billion by 2032 growing at a CAGR of 8.1% during the forecast period. Acute Ischemic Stroke (AIS) is a critical cerebrovascular event caused by an arterial occlusion, leading to reduced cerebral blood flow and potential neuronal damage. Emerging trends such as AI-driven stroke diagnostics and novel clot-retrieval devices are shaping market dynamics, fostering competition among pharmaceutical and medical device companies in the neurovascular sector.

According to the International Diabetes Federation's recent data, approximately 537 million people aged 20-79 years were living with diabetes worldwide in 2021, with projections indicating an increase to 643 million by 2030 and 783 million by 2045.

Market Dynamics:

Driver:

Rising stroke incidence

The increasing prevalence of acute ischemic stroke (AIS) globally is a significant driver for the market. Aging populations and the rising burden of cardiovascular diseases contribute to the growing incidence of stroke. Additionally, lifestyle factors such as sedentary habits, poor diet, and smoking further exacerbate the risk of stroke. Governments and healthcare organizations are also focusing on awareness campaigns to promote early detection and intervention. This surge in stroke cases is propelling the growth of the AIS diagnosis and treatment market.

Restraint:

Limited treatment window

One of the primary restraints in the AIS market is the narrow therapeutic window for effective treatment. The time-sensitive nature of stroke management limits the applicability of certain interventions, such as thrombolysis and thrombectomy. Delays in diagnosis or patient presentation to healthcare facilities often result in missed opportunities for optimal treatment. These challenges underscore the need for improved healthcare infrastructure and faster diagnostic protocols. The limited treatment window remains a critical barrier to market expansion.

Opportunity:

AI and telemedicine integration

The integration of artificial intelligence (AI) and telemedicine presents a significant opportunity for the AIS market. AI-powered diagnostic tools can enhance the accuracy and speed of stroke detection, enabling timely intervention. Telemedicine facilitates remote consultations, allowing specialists to guide treatment decisions in real-time, even in underserved regions. Furthermore, AI-driven predictive analytics can aid in identifying high-risk individuals, enabling preventive measures. The growing investment in digital health solutions is expected to drive innovation and growth in this segment.

Threat:

Risk of treatment-related complications

The potential for treatment-related complications poses a threat to the AIS market. Interventions such as thrombolytic therapy and mechanical thrombectomy carry risks of bleeding, infection, or vascular damage. Additionally, the high cost of advanced treatments and the associated risks may limit their adoption in resource-constrained settings. Ensuring patient safety while maintaining treatment efficacy remains a critical challenge. Addressing these concerns through improved protocols and safer therapeutic options is essential for market growth.

Covid-19 Impact:

The COVID-19 pandemic has had a mixed impact on the AIS diagnosis and treatment market. On one hand, the focus on healthcare infrastructure and the need for rapid diagnostics during the pandemic accelerated the adoption of advanced technologies. However, the pandemic highlighted the importance of telemedicine and remote monitoring, which are expected to play a larger role in post-pandemic stroke management.

The antiplatelet drugs segment is expected to be the largest during the forecast period

The Antiplatelet Drugs segment is expected to account for the largest market share during the forecast period due to their efficacy in preventing clot formation. These drugs are critical in the management of acute ischemic strokes, reducing the risk of recurrence. The widespread adoption of antiplatelet drugs in clinical practice is driven by their proven benefits in stroke prevention. Advances in drug formulations and delivery methods are enhancing patient compliance and outcomes. Moreover, segment's growth is further supported by the increasing incidence of stroke and the emphasis on preventive care and continuous research and development are expected to introduce more effective antiplatelet therapies, solidifying their market position.

The imaging techniques segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Imaging Techniques segment is predicted to witness the highest growth rate due to Innovations in imaging technology, such as CT scans and MRI, are improving diagnostic precision and speed. The growing demand for advanced imaging solutions is driven by the need for early and accurate stroke detection. Increased investment in healthcare infrastructure, particularly in developing regions, is expected to boost the adoption of imaging techniques. Additionally, continuous advancements in imaging modalities are enhancing their capabilities, leading to better patient outcomes and collaborations between healthcare providers and technology firms are likely to accelerate the adoption of cutting-edge imaging solutions.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to Increasing awareness about stroke symptoms and the importance of timely intervention is driving the demand for advanced diagnostic and treatment solutions. The presence of key market players and continuous investment in R&D further bolster the region's market position. Government initiatives aimed at improving stroke care are contributing to the growth. The rising prevalence of lifestyle-related risk factors, such as hypertension and diabetes, is also expected to fuel the market.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR due to rapidly developing healthcare infrastructure and increasing healthcare expenditure. Countries like China, India, and Japan are at the forefront, with significant investments in healthcare technology and infrastructure. The growing awareness about stroke and the importance of early diagnosis and treatment is boosting market demand. Favorable government policies and initiatives aimed at improving healthcare accessibility are also contributing to the growth. The increasing prevalence of stroke and related risk factors, such as hypertension and diabetes, is expected to further drive market expansion.

Key players in the market

Some of the key players in Acute ischemic stroke diagnosis and treatment market include Abbott Laboratories, BIOTRONIK SE & Co KG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Canon Medical Systems Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE Healthcare Technologies Inc., Genentech, Inc. by Roche Group, Hitachi, Ltd., Integral Diagnostics (IDX) Group, Koninklijke Philips N.V., Mediso Kft., Medtronic PLC and Memorial Health.

Key Developments:

In January 2025, Philips Healthcare planned to debut its Telestroke Connect Platform, a cloud-based telemedicine solution that links rural clinics with stroke specialists via augmented reality (AR). The platform will support live 3D imaging reviews and collaborative treatment planning, addressing gaps in access to specialized stroke care in underserved regions.

In March 2024, Siemens Healthineers launched the AI-Powered NeuroVision CT Suite, a next-generation imaging system designed to accelerate the detection of acute ischemic strokes. The suite integrates artificial intelligence to analyze brain scans in under 3 minutes, enabling rapid identification of blockages and guiding treatment decisions for thrombolysis or thrombectomy.

In February 2024, Medtronic introduced the Solitaire(TM) X Platinum+ Stent Retriever, an advanced thrombectomy device optimized for precision in removing blood clots. The device features enhanced flexibility and radial force, improving success rates in complex neurovascular anatomies while minimizing vessel trauma.

Drug Types Covered:

  • Thrombolytics
  • Antiplatelet Drugs
  • Anticoagulants
  • Neuroprotective Agents
  • Other Drug Types

Diagnosis Methods Covered:

  • Imaging Techniques
  • Blood Tests
  • Electrocardiogram
  • Other Diagnosis Methods

Treatments Covered:

  • Medication-Based Treatment
  • Surgical & Interventional Treatments
  • Other Treatments

End Users Covered:

  • Ambulatory Surgical Centers
  • Diagnostic Centers
  • Hospitals
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Thrombolytics
  • 5.3 Antiplatelet Drugs
  • 5.4 Anticoagulants
  • 5.5 Neuroprotective Agents
  • 5.6 Other Drug Types

6 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Diagnosis Method

  • 6.1 Introduction
  • 6.2 Imaging Techniques
    • 6.2.1 Computed Tomography (CT) Scan
    • 6.2.2 Magnetic Resonance Imaging (MRI)
    • 6.2.3 CT Angiography
    • 6.2.4 MR Angiography
  • 6.3 Blood Tests
  • 6.4 Electrocardiogram
  • 6.5 Other Diagnosis Methods

7 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Treatment

  • 7.1 Introduction
  • 7.2 Medication-Based Treatment
  • 7.3 Surgical & Interventional Treatments
  • 7.4 Other Treatments

8 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Ambulatory Surgical Centers
  • 8.3 Diagnostic Centers
  • 8.4 Hospitals
  • 8.5 Research Institutes
  • 8.6 Other End Users

9 Global Acute Ischemic Stroke Diagnosis and Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 BIOTRONIK SE & Co KG
  • 11.3 Boehringer Ingelheim International GmbH
  • 11.4 Boston Scientific Corporation
  • 11.5 Canon Medical Systems Corporation
  • 11.6 F. Hoffmann-La Roche Ltd.
  • 11.7 Fujifilm Holdings Corporation
  • 11.8 GE Healthcare Technologies Inc.
  • 11.9 Genentech, Inc. by Roche Group
  • 11.10 Hitachi, Ltd.
  • 11.11 Integral Diagnostics (IDX) Group
  • 11.12 Koninklijke Philips N.V.
  • 11.13 Mediso Kft.
  • 11.14 Medtronic PLC
  • 11.15 Memorial Health

List of Tables

  • Table 1 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Drug Type (2024-2032) ($MN)
  • Table 3 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Thrombolytics (2024-2032) ($MN)
  • Table 4 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Antiplatelet Drugs (2024-2032) ($MN)
  • Table 5 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Anticoagulants (2024-2032) ($MN)
  • Table 6 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Neuroprotective Agents (2024-2032) ($MN)
  • Table 7 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other Drug Types (2024-2032) ($MN)
  • Table 8 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 9 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Imaging Techniques (2024-2032) ($MN)
  • Table 10 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Computed Tomography (CT) Scan (2024-2032) ($MN)
  • Table 11 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Magnetic Resonance Imaging (MRI) (2024-2032) ($MN)
  • Table 12 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By CT Angiography (2024-2032) ($MN)
  • Table 13 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By MR Angiography (2024-2032) ($MN)
  • Table 14 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Blood Tests (2024-2032) ($MN)
  • Table 15 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Electrocardiogram (2024-2032) ($MN)
  • Table 16 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other Diagnosis Methods (2024-2032) ($MN)
  • Table 17 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Treatment (2024-2032) ($MN)
  • Table 18 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Medication-Based Treatment (2024-2032) ($MN)
  • Table 19 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Surgical & Interventional Treatments (2024-2032) ($MN)
  • Table 20 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other Treatments (2024-2032) ($MN)
  • Table 21 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By End Users (2024-2032) ($MN)
  • Table 22 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 23 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 24 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 25 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 26 Global Acute Ischemic Stroke Diagnosis and Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above. Wholesale Markets